NEUROMOD
8.10.2020 08:04:01 CEST | Business Wire | Press release
Neuromod Devices Limited (“Neuromod”), the Irish medical device company specialising in the treatment of chronic tinnitus, commonly described as ‘ringing in the ears’, has published the results of the Company’s TENT A1 (Treatment Evaluation of Neuromodulation for Tinnitus) clinical trial in this week’s edition of Science Translational Medicine in a paper titled: ‘Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study’.
The clinical trial was conducted between 2016 and 2019 and was designed to track changes in tinnitus symptom severity. The trial investigated the bimodal neuromodulation approach, using Neuromod’s non-invasive stimulation device that delivers sound to the ears and electrical stimulation to the tongue.
The study represents the largest and longest followed-up clinical trial ever conducted in the tinnitus field with 326 enrolled participants, providing evidence regarding the safety, efficacy and patient tolerability of bimodal neuromodulation for the treatment of tinnitus. 86.2% of treatment compliant participants reported an improvement in tinnitus symptom severity when evaluated after 12 weeks of treatment, with many experiencing sustained benefit 12 months post-treatment.
The study was conducted at the Wellcome Trust-HRB Clinical Research Facility, St. James’s Hospital, Dublin, Ireland and the Tinnituszentrum of the University Regensburg, Germany. There were consistent therapeutic outcomes across both clinical sites, with no SAEs Serious Adverse Events (SAEs related to the treatment and a high satisfaction rate across a large cohort of participants. A Medical Research Organization (NAMSA, Minneapolis, Minnesota, USA) guided and assisted the close-out process of Neuromod’s clinical trial.
The tinnitus treatment device, now branded as Lenire®, which was used in the study was developed by Neuromod and consists of wireless (Bluetooth®) headphones that deliver sequences of audio tones layered with wideband noise to both ears, combined with electrical stimulation pulses delivered to 32 electrodes on the tip of the tongue by a proprietary device trademarked as Tonguetip®. The timing, intensity and delivery of the stimuli are controlled by an easy to use handheld controller that each participant is trained to use. Before using the treatment for the first time, the device is configured to the patient’s hearing profile and optimised to the patient’s sensitivity level for tongue stimulation.
For the trial, participants were instructed to use the Lenire® device for 60 minutes daily for 12 weeks. Out of 326 enrolled participants, 83.7% used the device at or above the minimum compliance level of 36 hours over the 12-week treatment period. For the primary endpoints, participants achieved a statistically and clinically significant reduction in tinnitus symptom severity.
When treatment was completed, participants returned their device and were assessed at three follow-up visits up to 12 months. 66.5% of participants who filled out the exit survey (n=272) affirmed they had benefited from using the device and 77.8% (n=270) said they would recommend the treatment for other people with tinnitus.
Participants in the study were screened and selected based on a pre-defined list of inclusion and exclusion criteria to ensure the trial had a wide distribution sample of the tinnitus population. More information on the criteria can be found on https://www.clinicaltrials.gov/ using the identifier NCT02669069 and the full paper can be accessed here: https://www.neuromoddevices.com/tenta1results .
Dr Ross O’Neill, Founding CEO of Neuromod commented: “We are delighted to announce the publication of positive results from our TENT-A1 clinical trial, which has shown significant improvements in tinnitus symptoms in patients using our unique Lenire® device. There is a globally recognised clinical need for evidence-based treatments for tinnitus, such as Lenire®, due to the lack of effective options for this debilitating condition. Neuromod is proud to be at the cutting edge of efforts to research and develop new solutions that can contribute to solving this chronic condition that affects 10-15% of the population worldwide. We are committed to continuing our research in the field and to advance our unique chronic tinnitus treatment technology”.
Hubert Lim, Chief Scientific Officer of Neuromod commented: “I am truly proud of our Company’s ability to perform such a large-scale randomised clinical trial in two countries, enrolling 326 participants to demonstrate the safety and efficacy of a new solution for tinnitus. This study tracked the post-treatment therapeutic effects for 12 months, which is a first for the tinnitus field in evaluating the long-term outcomes of a medical device approach. The outcomes are very exciting and I look forward to continuing our work to develop a bimodal neuromodulation treatment to help as many tinnitus sufferers as possible.”
About Neuromod Devices Limited
Neuromod Devices Limited (“Neuromod”), headquartered in the Digital Hub, Dublin, Ireland, is a medical technology company, specialising in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions. The company was founded in 2010, by Dr. Ross O’Neill. The lead application of Neuromod’s technology is in the field of tinnitus, where Neuromod has completed extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder for which no standard of care has yet been established. Neuromod’s tinnitus treatment device Lenire® has been commercialised in Europe and is available in Ireland, Belgium and Germany. Tinnitus affects between 10 and 15% of the global population, and the lives of at least 1 in every 100 people worldwide are severely compromised because of the incessant nature of the illusory sound that is often described as a ringing or buzzing in the ears.
About Lenire®
Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment shown to soothe and relieve tinnitus in a large-scale clinical trial. Lenire® has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe. Further details on Lenire® including a list of providers can be found under www.lenire.com .
About Science Translational Medicine
The Science family of journals is published by the American Association for the Advancement of Science (AAAS), the world’s oldest and largest general science organization. The Science magazine has been at the centre of important scientific discovery since its founding in 1880, and continues to publish the very best in research across the sciences, with articles that consistently rank among the most cited in the world. Science Translational Medicine is an essential platform for peer-reviewed, multidisciplinary research driving the latest medical advances to complement the discoveries in the Science magazine.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005887/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release
Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release
Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene
Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release
Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req
From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release
The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
